Ascending as a new biopharmaceutical force

Vision 3×3

A Strategic Roadmap for Sustainable Growth

At Ascendis, we are working to build a leading, fully integrated biopharma company that provides meaningful improvement in patients’ lives. With the successful accomplishments of Vision 20/20, we have implemented a new strategic roadmap through 2025, Vision 3×3. The goal of Vision 3×3 is to achieve sustainable growth through multiple approaches:

  • Obtain regulatory approval for three endocrinology rare disease products:
    • TransCon hGH for pediatric growth hormone deficiency
    • TransCon PTH for adult hypoparathyroidism
    • TransCon CNP for achondroplasia
  • Create further growth of our endocrinology rare disease pipeline through:
    • Label expansion programs, with the goal of obtaining 9 indications in total
    • Global clinical reach, either directly or through partnerships
  • Build an integrated commercial business for the endocrinology rare disease franchise in North America and select European countries, and establish a global commercial presence with partners in other geographic areas
  • Create three independent therapeutic areas, each with a diversified pipeline built on TransCon technologies and our unique algorithm for product innovation. We have established oncology as the next independent therapeutic area

Introduced in January 2019, Vision 3×3 speaks to where we are today, with 3 potentially best-in-class endocrinology rare disease product candidates in clinical development. It also speaks to our aspirations—how we intend to multiply our success to address unmet patient needs.